Quote:

---

So, Merck would have benefitted with a much more robust combination clinical trial where the true results would be permitted to fully declare themselves.

Merck would have had nothing to lose except more Keytruda in participating in such a trial.

---

What they would lose is Keytruda being one of the pinnacle drugs in cancer. What is puzzling is why they didn't tender a Cytodyn buyout. Of course they may have and been rebuffed by Nader. Running a trial and showing leronlimab's superiority without owning the drug would do nothing but lead to a bidding war. I also wonder if their scientists misunderstand the drug like the FDA does.